Search Within

Saad Zafar Usmani

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (56)
  2. Journal Article (15)
  3. Research Letter (3)
  4. Correspondence (2)
Groups
  1. Epidemiology and Biostatistics (76)
  2. Department of Medicine (73)
  3. Hematologic Malignancies, Division of (73)
  4. Center for Hematologic Malignancies (71)
  5. Biostatistics Service (69)
  6. Myeloma (69)

More Groups

People
  1. Alexander Lesokhin (66)
  2. Urvi Shah (62)
  3. Kylee Maclachlan (59)
  4. Malin Hultcrantz (59)
  5. Sham Mailankody (59)
  6. Andriy Derkach (57)

More People

Years
  1. 2025 (3)
  2. 2024 (23)
  3. 2023 (30)
  4. 2022 (20)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (25)
  2. Blood (23)
  3. Journal of Clinical Oncology (10)
  4. Blood Cancer Journal (6)
  5. Blood Advances (3)
  6. New England Journal of Medicine (2)

More Publications

Publishers
  1. American Society of Hematology (26)
  2. Elsevier Inc. (26)
  3. American Society of Clinical Oncology (10)
  4. Nature Publishing Group (7)
  5. Massachusetts Medical Society (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (76)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Individualized risk in newly diagnosed multiple myeloma
    Meeting Abstract

    Maura, F.; Rajanna, A.; Ziccheddu, B.; Derkach, A.; Poos, A.; Maclachlan, K.; Boyle, E.; Hultcrantz, M.; Silva, A.; Jackson, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP cohort
    Meeting Abstract

    Parikh, R.; Castro, F.; Eustaquio, J. C.; Derkach, A.; Joseph, J.; Lesokhin, A. M.; Usmani, S. Z.; Shah, U. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save